Lataa...
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the primary treatment in treating with EGFR mutant nonsmall cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of the third-generation EGFR-TKI, osimertinib,...
Tallennettuna:
| Julkaisussa: | Medicine (Baltimore) |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Lippincott Williams & Wilkins
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7447427/ https://ncbi.nlm.nih.gov/pubmed/32846826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021826 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|